Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

ABSTRACT:

Introduction

Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally administered tyrosine kinase inhibitor of VEGF receptors-1, -2, and -3.

Methods

We conducted a multi-center phase II trial of cediranib in patients with unresectable, histologically-confirmed MM who had received ≤1 prior regimen of chemotherapy. The primary endpoint was objective response rate. Initial cediranib dosing was 45 mg daily during a 28-day cycle. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.

Results

Fifty-one patients enrolled

SUBMITTER: Campbell NP 

PROVIDER: S-EPMC4319647 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature